Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors

This study is ongoing, but not recruiting participants.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
City of Hope Medical Center
ClinicalTrials.gov Identifier:
First received: November 7, 2008
Last updated: February 10, 2016
Last verified: February 2016

RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs in chemotherapy, such as ifosfamide, carboplatin, and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving dasatinib together with ifosfamide, carboplatin, and etoposide may kill more tumor cells.

PURPOSE: This phase I/II trial is studying the side effects and best dose of dasatinib when given together with ifosfamide, carboplatin, and etoposide and to see how well they work in treating young patients with metastatic or recurrent malignant solid tumors.

Condition Intervention Phase
Brain and Central Nervous System Tumors
Childhood Germ Cell Tumor
Extragonadal Germ Cell Tumor
Kidney Cancer
Liver Cancer
Ovarian Cancer
Testicular Germ Cell Tumor
Unspecified Childhood Solid Tumor, Protocol Specific
Drug: carboplatin
Drug: dasatinib
Drug: etoposide phosphate
Drug: ifosfamide
Genetic: microarray analysis
Genetic: western blotting
Other: immunohistochemistry staining method
Other: laboratory biomarker analysis
Procedure: therapeutic conventional surgery
Radiation: radiation therapy
Phase 1
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Dasatinib With Ifosfamide, Carboplatin, Etoposide: A Pediatric Phase I/II Trial

Resource links provided by NLM:

Genetic and Rare Diseases Information Center resources: Anaplastic Large Cell Lymphoma Anaplastic Oligodendroglioma Angioimmunoblastic Lymphadenopathy With Dysproteinemia Angioimmunoblastic T-cell Lymphoma Bone Cancer Brain Stem Glioma, Childhood Brain Tumor, Childhood Burkitt Lymphoma Cerebellar Astrocytoma, Childhood Cerebral Astrocytoma, Childhood Choriocarcinoma Congenital Mesoblastic Nephroma Craniopharyngioma Embryonal Tumor With Multilayered Rosettes Ependymoma Ewing Sarcoma Ewing's Family of Tumors Extracranial Germ Cell Tumor, Childhood Extragonadal Germ Cell Tumor Germinoma Glioma Hodgkin Lymphoma Hodgkin Lymphoma, Childhood Kidney Cancer Liver Cancer Lymphoblastic Lymphoma Lymphoma, Large-cell Lymphoma, Large-cell, Immunoblastic Lymphomatoid Granulomatosis Lymphosarcoma Malignant Germ Cell Tumor Malignant Mesenchymal Tumor Medulloblastoma Medulloblastoma, Childhood Meningioma Neuroblastoma Neuroepithelioma Oligodendroglioma Osteosarcoma Ovarian Cancer Ovarian Germ Cell Tumor Pineoblastoma Pineoblastoma, Childhood Pineocytoma Plasmablastic Lymphoma Renal Cancer Rhabdoid Tumor Small Non-cleaved Cell Lymphoma Soft Tissue Sarcoma Spinal Cord Neoplasm Subependymal Giant Cell Astrocytoma Supratentorial Primitive Neuroectodermal Tumor Supratentorial Primitive Neuroectodermal Tumors, Childhood Testicular Cancer Uterine Sarcoma Wilms' Tumor Yolk Sac Tumor
U.S. FDA Resources

Further study details as provided by City of Hope Medical Center:

Primary Outcome Measures:
  • Maximum tolerated dose of dasatinib (Phase I) [ Time Frame: 28 days after start of course 1 ] [ Designated as safety issue: Yes ]
  • Toxicity as measured by NCI CTCAE v3.0 (Phase I) [ Time Frame: 28 days after start of course 1 ] [ Designated as safety issue: Yes ]
  • Overall survival at 1 year in patients with relapsed sarcoma (Phase II, Stratum A) [ Time Frame: 1 year after start of treatment ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Response rate prior to consolidation therapy as measured by RECIST criteria (Phase II) [ Time Frame: Prior to consolidation therapy ] [ Designated as safety issue: No ]
  • Progression-free survival (Phase II) [ Time Frame: 18 months after start of treatment ] [ Designated as safety issue: No ]
  • Exploratory correlative studies [ Time Frame: Day 14-21 of dasatinib treatment ] [ Designated as safety issue: No ]

Estimated Enrollment: 143
Study Start Date: September 2008
Estimated Primary Completion Date: September 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Dasatinib with Ifosfamide, Carboplatin, Etoposide Drug: carboplatin Drug: dasatinib Drug: etoposide phosphate Drug: ifosfamide Genetic: microarray analysis Genetic: western blotting Other: immunohistochemistry staining method Other: laboratory biomarker analysis Procedure: therapeutic conventional surgery Radiation: radiation therapy

Detailed Description:



  • To determine the maximum tolerated dose (MTD) of dasatinib when given immediately following ifosfamide, carboplatin, and etoposide phosphate (D-ICE) as a re-induction regimen in young patients with metastatic or recurrent malignant solid tumors. (Phase I)
  • To describe and define the toxicities of D-ICE in these patients. (Phase I)
  • To determine the safety and feasibility of prolonged administration of single-agent dasatinib following completion of 2-6 courses of D-ICE in these patients. (Phase I)
  • To estimate the overall survival, progression-free survival, and time to progression in patients treated with D-ICE at the MTD followed by single-agent dasatinib. (Phase II)
  • To estimate the response rate to two courses of D-ICE when given at the MTD in these patients. (Phase II)


  • To determine the phosphotyrosine state of SRC family kinases and related signaling pathways, including FAK, STAT3, VEGFR, AKT, EGFR, KIT, EPHA2, and PDGFR, in paraffin-embedded tumor samples as measured by immunohistochemistry prior to and during treatment with dasatinib.
  • To assess gene expression profiling in fresh frozen tissue samples as measured by microarray analysis (Affymetrix GeneChips) at baseline to identify molecular signatures that may predict response to dasatinib.
  • To correlate biomarkers and molecular signatures with dasatinib dosage, toxicity, and antitumor activity.
  • To evaluate the effect of dasatinib on phosphorylation of SRC family kinases in peripheral blood mononuclear cell samples as a surrogate marker of response prior to treatment with dasatinib, at days 14-21 or when WBC ≥ 500/μL, during each treatment course, at the time of local control, and at the time of progression.

OUTLINE: This is a multicenter, phase I, dose-escalation study of dasatinib followed by a phase II study. Patients enrolled in phase II are stratified according to disease.

Patients receive D-ICE comprising oral dasatinib twice daily on days 5-21, ifosfamide IV over 1 hour and etoposide phosphate IV over 1 hour on days 1-5, and carboplatin IV over 1 hour on days 1 and 2. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo radiotherapy and/or surgery (consolidation therapy) after 2, 4, or 6 courses of D-ICE. After completion of consolidation therapy, patients receive oral dasatinib twice daily for up to 6 months in the absence of disease progression or unacceptable toxicity.

Tumor tissue and peripheral blood mononuclear cell (PBMC) samples are collected periodically for correlative laboratory studies. PBMCs are analyzed by western blotting for total and phospho-SRC, phospho-FAK, and other relevant biomarkers. Tumor tissue samples are analyzed by IHC for total and phospho-SRC, phospho-FAK, phospho-STAT3, phospho-KIT, and phospho-PDGFR, EPHA2, and VEGF. Tumor tissue samples are also analyzed by microarray gene expression profiling to define a potential molecular signature or gene expression pattern that may predict response to dasatinib.

After completion of study treatment, patients are followed periodically.


Ages Eligible for Study:   1 Year to 25 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


  • Histologically confirmed malignant solid tumor that did not respond to or relapsed after standard first-line chemotherapy or other antineoplastic therapy (if the standard therapy for the tumor is generally recognized to be beneficial)

    • Must have been initially diagnosed with malignancy prior to 25 years of age
    • Radiographic, nuclear image, or biopsy confirmation of disease within the past 4 weeks
  • Meets one of the following criteria:

    • Phase I: Relapsed/refractory malignant solid tumor (excluding CNS tumors)

      • Patients with recurrent or metastatic disease that was completely resected just prior to study entry are eligible
    • Phase II: Patients are stratified according to one of the following diagnoses:

      • Stratum A: Relapsed sarcoma (rhabdomyosarcoma, osteosarcoma, or Ewing sarcoma)
      • Stratum B: Other relapsed solid tumors, including any of the following:

        • Other soft tissue sarcomas
        • Kidney tumors
        • Lymphoma
        • CNS tumors*
        • Other solid tumors (neuroblastoma, gonadal and germ cell tumors, liver tumors, or miscellaneous tumors)
      • Stratum C: Newly diagnosed, poor-risk metastatic sarcoma consisting of unresectable pulmonary metastases (≥ 6 nodules) and/or disease involving multiple bones or other organs NOTE: *Patients with recurrent primary CNS tumors are eligible for the phase II portion of this study provided there are no significant intratumoral bleeding toxicities seen in either COG pediatric phase I studies of dasatinib or the phase I portion of this study
  • Radiographically measurable disease (Phase II)

    • Measurable disease is not required for patients who are enrolled in the phase I portion of this study
  • No bone marrow involvement (Phase I)

    • Patients with bone marrow involvement are eligible for the phase II portion of this study provided they are not known to be refractory to red cell or platelet transfusions


  • Lansky performance status (PS) 50-100% (patients 1-16 years of age) or Karnofsky PS 50-100% (patients > 16 years of age)
  • Life expectancy ≥ 8 weeks
  • ANC > 1,000/μL
  • Platelet count > 75,000/μL
  • Creatinine clearance or GFR ≥ 70 mL/min OR creatinine < 1.5 times upper limit of normal (ULN)
  • Bilirubin < 1.5 times ULN for age
  • SGOT or SGPT < 2.5 times ULN for age (< 5 times ULN if liver involvement by tumor)
  • Ejection fraction normal by MUGA OR shortening fraction > 28%
  • No evidence of cardiac arrhythmias requiring therapy
  • Corrected QTc interval < 450 msecs
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • Able to comply with the safety monitoring requirements of this study
  • No uncontrolled infection
  • No swallowing dysfunction that would preclude oral medication intake

    • Gastric or jejunal tube allowed provided it is functioning
  • No history of significant bleeding disorder unrelated to cancer, including the following:

    • Diagnosed congenital bleeding disorders (e.g., von Willebrand's disease)
    • Acquired bleeding disorder diagnosed within the past year (e.g., acquired anti-factor VIII antibodies)
    • Ongoing or recent (within the past 3 months) significant gastrointestinal bleeding


  • See Disease Characteristics
  • Recovered from all prior therapy
  • At least 7 days since prior and no concurrent drugs known to cause Torsades de Pointes, including the following:

    • Procainamide or disopyramide
    • Amiodarone, sotalol, ibutilide, or dofetilide
    • Erythromycin or clarithromycin
    • Chlorpromazine, haloperidol, mesoridazine, or thioridazine
    • Bepridil, droperidol, methadone, arsenic, chloroquine, domperidone, halofantrine, levomethadyl, pentamidine, sparfloxacin, or lidoflazine
  • At least 3 weeks since prior chemotherapy (6 weeks for nitrosourea-containing therapy)
  • At least 3 months since prior ifosfamide, carboplatin, and/or etoposide phosphate in the exact combination and dosage as administered in this study
  • More than 7 days since prior filgrastim (G-CSF), sargramostim (GM-CSF), or interleukin-11
  • More than 14 days since prior pegfilgrastim
  • More than 30 days since prior epoetin alfa
  • No prior cranial-spinal irradiation at doses > 2,400 cGy
  • No prior radiotherapy, including total-body irradiation, to > 50% of the bone marrow space
  • No other concurrent investigational drugs or anticancer agents
  • No concurrent enzyme-inducing anticonvulsants (e.g., phenytoin, phenobarbital, felbamate, primdone, oxcarbazepine, or carbamazepine)
  • No concurrent anti-thrombotic or anti-platelet agents (e.g., warfarin, heparin, low molecular weight heparin, aspirin, ibuprofen, or other NSAIDs)
  • No concurrent CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, or voriconazole)
  • No concurrent highly active antiretroviral therapy for HIV-positive patients
  • No concurrent St. John's wort
  • No IV bisphosphonates during the first 8 weeks of dasatinib therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00788125

United States, California
City of Hope Comprehensive Cancer Center
Duarte, California, United States, 91010-3000
Sponsors and Collaborators
City of Hope Medical Center
National Cancer Institute (NCI)
Principal Investigator: Judith K. Sato, MD Beckman Research Institute
  More Information

Responsible Party: City of Hope Medical Center
ClinicalTrials.gov Identifier: NCT00788125     History of Changes
Other Study ID Numbers: 07053  P30CA033572  CHNMC-07053  CA180 121  CDR0000617760 
Study First Received: November 7, 2008
Last Updated: February 10, 2016
Health Authority: United States: Food and Drug Administration

Keywords provided by City of Hope Medical Center:
previously treated childhood rhabdomyosarcoma
metastatic childhood soft tissue sarcoma
metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
metastatic osteosarcoma
recurrent childhood rhabdomyosarcoma
recurrent childhood soft tissue sarcoma
recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
recurrent osteosarcoma
unspecified childhood solid tumor, protocol specific
recurrent Wilms tumor and other childhood kidney tumors
recurrent neuroblastoma
stage 4S neuroblastoma
childhood extracranial germ cell tumor
childhood malignant ovarian germ cell tumor
childhood malignant testicular germ cell tumor
childhood teratoma
clear cell sarcoma of the kidney
childhood renal cell carcinoma
recurrent renal cell cancer
congenital mesoblastic nephroma
cystic nephroma
peripheral primitive neuroectodermal tumor of the kidney
rhabdoid tumor of the kidney
disseminated neuroblastoma
recurrent malignant testicular germ cell tumor
recurrent ovarian germ cell tumor
recurrent childhood liver cancer
stage IV childhood liver cancer
angioimmunoblastic T-cell lymphoma
stage IV childhood Hodgkin lymphoma

Additional relevant MeSH terms:
Central Nervous System Neoplasms
Liver Neoplasms
Neoplasms, Germ Cell and Embryonal
Nervous System Neoplasms
Testicular Neoplasms
Digestive System Diseases
Digestive System Neoplasms
Endocrine Gland Neoplasms
Endocrine System Diseases
Genital Diseases, Male
Genital Neoplasms, Male
Gonadal Disorders
Liver Diseases
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplasms, Neuroepithelial
Nervous System Diseases
Neuroectodermal Tumors
Neuroectodermal Tumors, Primitive
Neuroectodermal Tumors, Primitive, Peripheral
Testicular Diseases
Urogenital Neoplasms
Etoposide phosphate

ClinicalTrials.gov processed this record on May 24, 2016